Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Dexamethasone intravitreal implant Ozurdex to treat pseudophakic cystoid macular edema: case series

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Presented Poster Session: Cataract Surgery Complications and Management

Session Date/Time: Saturday 05/09/2015 | 09:30-10:50

Paper Time: 10:00

Venue: Poster Village: Pod 1

First Author: : M.Castilla SPAIN

Co Author(s): :    L. Sararols Ramsay   M. Guarro           

Abstract Details

Purpose:

To share our experience using dexamethasone intravitreal implant (DEX Implant 0.7 mg, Ozurdex; Allergan, Irvine, CA) for treatment of patients with pseudophakic cystoid macular edema (PCME) after cataract surgery.

Setting:

Servei Integral Oftalmologia Valles Oriental (SIOVO): Hospital General de Catalunya and Hospital de Granollers.

Methods:

Data from all patients developing PCME after cataract surgery and treated with DEX 0.7mg intravitreal implant were reviewed. A total of 9 cases were retrospectively collected, 6 cases after uneventful phaco surgery and 3 cases after complicated phaco that needed vitrectomy. Details of previous sistemic and ocular pathology, cataract surgery, previous theraphy for PCME, BCVA, Spectral Domain Optical Coherence Tomography (OCT) measurements, presence or not of vitreomacular adhesion or traction, Intraocular pressure (IOP) and Ophthalmologic examination findings were recorded, as well as adverse effects related with intravitreal Ozurdex implant.

Results:

5 female and 4 male, average age of 73, average time from surgery was 4.3 months in the uneventful phaco and 7.2 months in the complicated cases. 4 patients had received previos treatment for PCME (2 intravitreal Lucentis and 4 subtenon triamcinolone). Regarding complications: 33.3% developed increased IOP and one case presented corneal decompensation and needs penetrating queratoplasthy. OCT measurements improved in all cases and BCVA improved to 20/25 in 50% of the uneventful cases and improved an average of 7 letters in the complicated phaco cases.

Conclusions:

The dexamethasone Ozurdex implant is an effective and mostly safe treatment that gave us excellent results and few adverse events and could be a good option specially for cases of PCME in uneventful phaco surgeries and multifocal IOL.

Financial Interest:

NONE

Back to previous